Clinical trials: Severe Alcohol Use Disorder, open to volunteers
Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD)
Pregnenolone Treatment for Alcohol Use Disorder and Major Depressive Disorder
This study will evaluate whether pregnenolone is an effective treatment for adults with Alcohol Use Disorder (AUD) and Major Depressive Disorder (MDD).
- Trial name
- PREG-AUD-RO1 (NCT07734701)
- Testing
- Pregnenolone
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Sherwood Brown, MD, PhD
Alcohol-associated Hepatitis
Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial
This is a multicenter, randomized, double-blinded, placebo-controlled trial focused on the treatment of severe alcohol-associated hepatitis (sAH) and alcohol use disorder (AUD).
- Trial name
- ITAALD (NCT07060638)
- Testing
- IL-22, Prednisone, Acamprosate
- Where
- 6 sites in United States
- Volunteers
- 216 people
- Sponsor
- Samer Gawrieh
Depression - Major Depressive Disorder, Schizophenia Disorder
A Novel Blood Test as a Biomarker in Mental Health
This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in patients at the Royal Columbian Hospital…
- Conditions
- Depression - Major Depressive Disorder, Schizophenia Disorder, Psychosis, Mania (Neurotic)
- Trial name
- LEADING-MH (NCT06856161)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Fraser Health
Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD)
Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)
To assess the safety, feasibility and preliminary efficacy of ketamine-enhanced therapy (KET) for alcohol use disorder (AUD) and comorbid major depressive disorder (MDD) in an open-label, single arm, pilot clinical trial.
- Conditions
- Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD), Comorbidities and Coexisting Conditions
- Trial name
- KET-DUAL (NCT07247370)
- Testing
- Ketamine, Cognitive Behavioural Therapy
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- South West Sydney Local Health District
Depression - Major Depressive Disorder, Anxiety
Deaf CBT-TS to Reduce Suicide Risk
The goal of this clinical trial is to learn if a short, Zoom-based intervention, Cognitive Behavioral Therapy for Treatment-Seeking for Deaf Individuals (Deaf CBT-TS) can change beliefs about mental health treatment and increase…
- Conditions
- Depression - Major Depressive Disorder, Anxiety, PTSD - Post Traumatic Stress Disorder, Insomnia
- Trial name
- NCT07279363
- Testing
- Deaf CBT-TS
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Rochester
Severe Alcoholic Hepatitis
LiverTREM-1: Hepatic TREM-1 Expression and Prognosis in Severe Alcoholic Hepatitis
Background \& Rationale Severe alcohol-related hepatitis (SAH) is a serious condition with a 3-month mortality rate of ~30%. Diagnosis and prognosis are complex due to non-specific and insensitive clinical, biological, and…
- Trial name
- Liver TREM-1 (NCT07176741)
- Testing
- TREM-1 expression (via immunohistochemistry) between SAH patients and controls
- Volunteers
- 300 people
- Sponsor
- Central Hospital, Nancy, France
Alcohol Use Disorder, Alcoholic Hepatitis
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
Given the severe consequences of alcohol relapse following liver transplantation for alcoholic hepatitis (AH-LT), it is critical to accurately identify alcohol use and implement alcohol interventions early in the post-transplant…
- Trial name
- NCT03845205
- Testing
- Integrated AUD Treatment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Depression - Major Depressive Disorder, Alcohol Use Disorder
ACT_for Alcohol Use Disorder and Depression
Alcohol use disorders (AUDs) and depressive disorders frequently coexist, complicating the clinical management of patients suffering from them.
- Trial name
- NCT06620276
- Testing
- Acceptance and Commitment Therapy, Ketamine
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Alcohol Use Disorder
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
- Trial name
- RENEW-ALC-1 (NCT07219966)
- Testing
- LY3537031
- Where
- 117 sites in United States, Belgium and 6 more
- Volunteers
- 1,100 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder (MDD), Anxiety Disorder
Identification and Molecular Characterisation of Urban-environmental Stress Patterns Affecting Mental Illness
Mental disorders have become a major contributor to the global burden of non-communicable diseases, with disability-adjusted life years (DALYs) attributable to these conditions continuing to rise.
- Conditions
- Major Depressive Disorder (MDD), Anxiety Disorder, Alcohol Use Disorder (AUD)
- Trial name
- NCT07571226
- Testing
- wearable monitoring devices
- Where
- 3 sites in China
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Severe Alcohol Use Disorder (DSM 5)
Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation : CBD-OH
Randomized clinical trial of 11 days Cannabidiol versus placebo as an adjunctive treatment during inpatient alcohol detoxification to improve abstinence in patients with severe alcohol use disorder.
- Trial name
- CBD-OH (NCT05860699)
- Testing
- Half dose CBD, Full dose CBD
- Where
- 12 sites in France
- Volunteers
- 210 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alcohol Abuse, Alcohol Use Disorder
The Effect of Comorbid Alcohol/Substance Use
Study Design This study was designed as a comparative, cross-sectional case-control study examining the effect of comorbid alcohol and substance use disorder (ASUD) on clinical course and social inclusion among individuals with…
- Conditions
- Alcohol Abuse, Alcohol Use Disorder, Substance Use Disorders, Severe Mental Disorder
- Trial name
- NCT07692984
- Testing
- case (comorbid diagnosis), control
- Where
- Turkey (Türkiye)
- Volunteers
- 297 people
- Sponsor
- Abant Izzet Baysal University
Alcohol Use Disorder, Severe
Impact of Omega 3 in Alcohol Use Disorder
The goal of this clinical trial is to investigate the biological pathways underlying the beneficial effect of omega-3 polyunsaturated fatty acids (n-3 PUFA) on mental health in patients with alcohol use disorder.
- Trial name
- W3-AUD (NCT05899660)
- Testing
- Active Comparator: Omega-3
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Université Catholique de Louvain
Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD)
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder
The goal of this clinical trial is to determine the safety and efficacy of psilocybin assisted Therapy (PAT) in individuals with comorbid Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).
- Trial name
- NCT07405606
- Testing
- Psilocybin 25 mg
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Episode (MDE), Major Depressive Disorder (MDD)
LHC-CIDI-5 in Hong Kong
The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12…
- Conditions
- Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Persistent Depressive Disorder (PDD), Suicidal Ideation
- Trial name
- NCT06804525
- Testing
- CIDI-5, LHC-CIDI-5
- Where
- Hong Kong
- Volunteers
- 2,500 people
- Sponsor
- The University of Hong Kong
Alcohol Use Disorder
Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder
This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison…
- Trial name
- NCT07296094
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Brigham and Women's Hospital
Alcohol Use Disorder
Social Cognition in Severe Alcohol Use Disorder
With 41,000 deaths per year, alcohol consumption is the second leading cause of preventable mortality in France. Nearly 3.4% of adults engage in excessive and chronic alcohol use, meeting criteria for Severe Alcohol Use Disorder…
- Trial name
- COSMO (NCT07464613)
- Testing
- Analysis of social functioning and social cognition processes
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CHU de Reims